Extended Interval Dosing Natalizumab and impact on neuropsychological deficits in Relapsing-Remitting Multiple Sclerosis

Background: Cognitive impairment and neuropsychiatric symptoms are frequently reported in Relapsing-Remitting Multiple Sclerosis (RRMS). Natalizumab (NTZ) is usually administered on a 4-weekly Standard Interval Dosing (SID) schedule. However, Extended Interval Dosing (EID) at 6–8 weekly intervals ha...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Eileen J. McManus, Karen M. Clark, Christopher Frampton, Jamie A.B. Macniven, Jan Schepel
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	SAGE Publishing 2022-01-01
Edice:	Multiple Sclerosis Journal - Experimental, Translational and Clinical
On-line přístup:	https://doi.org/10.1177/20552173211070752
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!